The US FDA has approved Bayer's Sunharbo drug to prevent recurrent strokes. According to the Wall Street Journal, the drug reduces the risk of a second attack by 26% without increasing the likelihood of internal bleeding. The cost of a 30-day course will be $748.5. Analysts expect annual sales of the drug to reach $4.5 billion, which will allow Bayer to offset losses from patent expirations on other drugs.

The US FDA has approved Bayer's Sunharbo drug to prevent recurrent strokes. According to the Wall Street Journal, the drug reduces the risk of a second attack by 26% without increasing the likelihood of internal bleeding. The cost of a 30-day course will be $748.5. Analysts expect annual sales of the drug to reach $4.5 billion, which will allow Bayer to offset losses from patent expirations on other drugs.